The Food and Drugs Authority (FDA) has announced its intention to appeal the recent High Court ruling in favor of Tobinco Pharmaceuticals Ltd.
The FDA disagrees with the decision, citing grounds for appeal.
Although details of the appeal grounds are yet to be disclosed, the FDA is determined to exercise its right to appeal.
The FDA remains committed to upholding the judicial process and adhering to the rule of law, ensuring that the matter is fully resolved.
“The Authority respectfully disagrees with the decision and intends to exercise its right to appeal. The FDA remains committed to upholding the judicial process and adhering to the rule of law… We will follow due process until the matter is fully resolved.”
The regulatory body also rejected claims of negligence against its Chief Executive Officer (CEO) Dr. Delese Darko.
“The Authority informs the public that this case stems from actions taken in 2013… The leadership of the organisation have provided a defence to the courts at all material times,” the FDA stated.
The FDA emphasized that it “consistently and vigorously” responded to the action initiated against it in 2019.
